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Summary
Background Scarce data are available on what variables affect the risk of transmission of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), the development of symptomatic COVID-19, and, particularly, the relationship 
with viral load. We aimed to analyse data from linked index cases of COVID-19 and their contacts to explore factors 
associated with transmission of SARS-CoV-2.
Methods In this cohort study, patients were recruited as part of a randomised controlled trial done between March 17 
and April 28, 2020, that aimed to assess if hydroxychloroquine reduced transmission of SARS-CoV-2. Patients with 
COVID-19 and their contacts were identified by use of the electronic registry of the Epidemiological Surveillance 
Emergency Service of Catalonia (Spain). Patients with COVID-19 included in our analysis were aged 18 years or 
older, not hospitalised, had quantitative PCR results available at baseline, had mild symptom onset within 5 days 
before enrolment, and had no reported symptoms of SARS-CoV-2 infections in their accommodation or workplace 
within the 14 days before enrolment. Contacts included were adults with a recent history of exposure and absence of 
COVID-19-like symptoms within the 7 days preceding enrolment. Viral load of contacts, measured by quantitative 
PCR from a nasopharyngeal swab, was assessed at enrolment, at day 14, and whenever the participant reported 
COVID-19-like symptoms. We assessed risk of transmission and developing symptomatic disease and incubation 
dynamics using regression analysis. We assessed the relationship of viral load and characteristics of cases (age, sex, 
number of days from reported symptom onset, and presence or absence of fever, cough, dyspnoea, rhinitis, and 
anosmia) and associations between risk of transmission and characteristics of the index case and contacts.
Findings We identified 314 patients with COVID-19, with 282 (90%) having at least one contact (753 contacts in total), 
resulting in 282 clusters. 90 (32%) of 282 clusters had at least one transmission event. The secondary attack rate was 
17% (125 of 753 contacts), with a variation from 12% when the index case had a viral load lower than 1 × 10⁶ copies per 
mL to 24% when the index case had a viral load of 1 × 10¹⁰ copies per mL or higher (adjusted odds ratio per log10 
increase in viral load 1·3, 95% CI 1·1–1·5). Increased risk of transmission was also associated with household contact 
(3·0, 1·59–5·65) and age of the contact (per year: 1·02, 1·01–1·04). 449 contacts had a positive PCR result at baseline. 
28 (6%) of 449 contacts had symptoms at the first visit. Of 421 contacts who were asymptomatic at the first visit, 
181 (43%) developed symptomatic COVID-19, with a variation from approximately 38% in contacts with an initial 
viral load lower than 1 × 10⁷ copies per mL to greater than 66% for those with an initial viral load of 1 × 10¹⁰ copies per 
mL or higher (hazard ratio per log10 increase in viral load 1·12, 95% CI 1·05–1·20; p=0·0006). Time to onset of 
symptomatic disease decreased from a median of 7 days (IQR 5–10) for individuals with an initial viral load lower 
than 1 × 10⁷ copies per mL to 6 days (4–8) for those with an initial viral load between 1 × 10⁷ and 1 × 10⁹ copies per mL, 
and 5 days (3–8) for those with an initial viral load higher than 1 × 10⁹ copies per mL.
Interpretation In our study, the viral load of index cases was a leading driver of SARS-CoV-2 transmission. The risk of 
symptomatic COVID-19 was strongly associated with the viral load of contacts at baseline and shortened the 
incubation time of COVID-19 in a dose-dependent manner.
Funding YoMeCorono, Generalitat de Catalunya.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Introduction
According to current evidence, COVID-19 is primarily 
transmitted from person to person through respiratory 
droplets, as well as indirect contact through transfer of 
the virus from contaminated fomites to the mouth, 
nose, or eyes.1,2 As with most respiratory viral infections, 
some transmission through smaller aerosols is likely 
to occur, but their relative contribution compared 
with droplets remains unclear. Several outbreak 
investigation reports have shown that COVID-19 
transmission can be particularly effective in confined 
indoor spaces such as workplaces, including factories, 
churches, restaurants, shopping centres, and health-
care settings.3–6 In Spain and many other countries, 
health-care workers have had a high rate of COVID-19 
infection.7
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The availability of data regarding the factors that might 
enhance transmission is essential for designing inter-
ventions to control the spread of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). Available data 
provide information on the risk of transmission related 
to the place and duration of exposure and the use of 
respiratory and eye protection,1,3–5,8 but not on other 
factors related to the characteristics of index cases and 
their contacts. Over the course of infection, the virus has 
been identified in respiratory tract specimens 1–2 days 
before the onset of symptoms, and it can persist for 
prolonged periods, over several weeks after the onset 
of symptoms in mild cases.9 However, the detection of 
viral RNA by PCR does not necessarily equate with 
infectivity, and the exact relationship between viral load 
and risk of transmission from a case is still not clear.10,11 
Studies investigating case-contact pairs have reported 
highly variable secondary attack rates (ie, ranging from 
0·7% to 75%), depending on the type of exposure–
duration, place, pre-spymptomatic or post-symptomatic.12–15
Another challenge for public health interventions is 
the risk stratification of individuals who are infected 
for developing symptomatic illness. A living systematic 
review estimated that the proportion of PCR-positive 
infected contacts that progress to symptomatic disease is 
approximately 70–80%.16,17 Mean or median incubation 
period has been consistently estimated to be between 5 to 
7 days.18–20 Although studies have suggested that the viral 
load of cases might be associated with risk of disease or 
transmission, no published data so far have directly 
addressed this question, and little is known about 
factors that might contribute to variation on the risk of 
developing COVID-19 symptoms or the incubation 
periods among individuals who are infected.
The overall aim of this study was to evaluate transmission 
dynamics of SARS-CoV-2 in the context of a trial of post-
exposure prophylaxis. Specifically, the objectives of our 
study were threefold: to investigate the association 
between clinical and demographic features of cases and 
viral load, to evaluate the effect of viral load on SARS-CoV-2 
transmission to close contacts, and to determine the 
influence of viral load in the exposed individuals on 
development of symptoms and on the incubation period.
Methods
Study design
This study was a post-hoc analysis of data collected in 
the BCN PEP CoV-2 Study (NCT04304053), a cluster-
randomised trial that included individuals with PCR-
confirmed COVID-19 and their close contacts. The trial 
occurred between March 17 and April 28, 2020, during the 
initial wave of the SARS-CoV-2 outbreak, in three of 
Research in context
Evidence before this study
On Sept 20, 2020, we searched PubMed for articles reporting on 
factors influencing transmission of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and the risk of 
developing symptomatic COVID-19. Search terms included 
“COVID-19”, “SARS-CoV-2”, “transmission”, “incubation time”, 
and “risk”, with no language restrictions. Various authors had 
reported on retrospective analyses of clusters of index cases and 
their corresponding contacts, as well as series of patients who 
developed symptomatic COVID-19 after a positive PCR result. 
Besides describing the secondary attack rate, these studies 
identified risk factors for transmission associated with the place 
and duration of exposure and not using personal protective 
equipment. A single study suggested that individuals who were 
symptomatic might be more likely to transmit than those 
without symptoms, but we found no clear evidence regarding 
the influence of viral load of the index case on transmission risk. 
Similarly, although various retrospective series of patients with 
positive PCR results had reported incubation times elsewhere, 
the characteristics of index case and contacts that might 
influence the risk of developing symptomatic COVID-19 and the 
time to this event had been barely addressed.
Added value of this study
We analysed data from a large cluster-randomised clinical trial 
on post-exposure therapy for COVID-19 that provided new 
information on SARS-CoV-2 transmission dynamics. Several 
design components add value to this dataset. Notably, 
quantitative PCR was available for the index cases to estimate 
risk of transmission. Additionally, quantitative PCR was also 
done on asymptomatic contacts at the time of enrolment 
allowing us to investigate the dynamics of symptomatic 
disease onset among them. We found that the viral load of 
the index case was the leading determinant of the risk of 
SARS-CoV-2 PCR positivity among contacts. Among contacts 
who were SARS-CoV-2 PCR positive at baseline, viral load 
significantly influenced the risk of developing the 
symptomatic disease in a dose-dependent manner. 
This influence also became apparent in the incubation time, 
which shortened with increasing baseline viral loads.
Implications of all the available evidence
Our results provide important insights into the knowledge 
regarding the risk of SARS-CoV-2 transmission and COVID-19 
development. The fact that the transmission risk was 
primarily driven by the viral load of index cases, more than 
other factors such as their symptoms or age, suggests that all 
cases should be considered potential transmitters irrespective 
of their presentation and encourages the assessment of viral 
load in patients with a larger number of close contacts. 
Similarly, our results regarding the risk and expected time to 
developing symptomatic COVID-19 encourage risk 
stratification of newly diagnosed SARS-CoV-2 infections on 
the basis of the initial viral load.
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nine health-care areas in Catalonia (northeast Spain)—
Catalunya Central, Àmbit Metropolità Nord, and Barcelona 
Ciutat—with a total target population of 4 206 440 people. 
The study protocol of the BCN PEP CoV-2 Study was 
approved by the ethics committee of Hospital Germans 
Trias Pujol (Badalona, Spain). Written informed consent 
was obtained from all participants. Full details of the 
original study are reported elsewhere.21
COVID-19 cases were identified by use of the electronic 
registry of the Epidemiological Surveillance Emergency 
Service of Catalonia of the Department of Health.22 
Following government ordinance, the surveillance service 
registered all new COVID-19 diagnoses that occurred 
from March 16, 2020 onwards. The surveillance system 
included active tracing of all contacts with recent history 
of exposure, defined as being in contact with a case of 
SARS-CoV-2 confirmed by PCR within 2 m of distance for 
more than 15 min.
Study participants
All patients with COVID-19 included in our analysis were 
adults (aged 18 years or older) who were not hospitalised 
and had quantitative PCR results available at baseline, 
mild symptom onset within 5 days before enrolment, and 
no reported symptoms of SARS-CoV-2 infections in their 
accommodation (ie, household or nursing home) or 
workplace within the 14 days before enrolment. Contacts 
selected for the analysis were adults with a recent history 
of exposure and absence of COVID-19-like symptoms 
within the 7 days preceding enrolment. Contacts were 
exposed to the index case as either a health-care worker, a 
household contact, a nursing home worker, or a nursing 
home resident.
We selected all eligible individuals within the original 
trial population for each of the three analyses done in this 
study. As in the original trial, we found no evidence of an 
effect of hydroxychloroquine on either transmission or 
development of symptomatic disease; therefore, we 
included individuals from both groups of the trial in this 
study. First, all COVID-19 cases with quantitative PCR 
data were included in an analysis of the association 
between clinical and demographic features of cases and 
viral load. Second, we identified factors associated with 
transmission using all clusters of an index case (ie, a 
COVID-19 case with at least one close contact) and their 
corresponding contacts for which quantitative viral load 
was available for the index case. Finally, we assessed the 
risk of developing symptomatic disease and the variation 
in the incubation period among all contacts with a 
positive PCR result at baseline, irrespective of available 
data of their index case.
Study procedures and data collection
A dedicated outbreak field team visited cases and contacts 
at home or nursing home on days 1 (enrolment) and 14. 
At the first clinical assessment on day 1, the team did 
a baseline assessment, including a questionnaire 
for symptoms of COVID-19, and collected relevant epide-
mio logical information by use of a structured interview: 
time of first exposure to the index case, place of contact 
(hospital, home, or nursing care facility), routine use of a 
mask by the contact when in close proximity to the index 
case and sleep location concerning the index case (eg, 
same room or same house). Symptom surveillance 
consisted of active monitoring by phone on days 3 and 7, 
a home visit on day 14, and passive monitoring whenever 
the participants developed symptoms. Participants who 
developed symptoms were visited the same day they 
notified the symptom onset (unscheduled visits) by the 
field team, who recorded the date of symptom onset, type 
of symptoms from a prespecified checklist, and symptom 
severity, graded on a scale of 1 to 4.
All participants underwent serial SARS-CoV-2 PCR test 
and viral load titration from nasopharyngeal swabs on 
day 1 and day 14 and on any unscheduled visit when the 
participant notified the onset of COVID-19 symptoms 
(appendix 2 p 1). The detection of SARS-CoV-2 virus 
was done by PCR from nasopharyngeal swabs at SYNLAB 
Diagnostics (Barcelona, Spain) by use of the TaqMan 
2019-nCoV assay kit according to the manufacturer’s 
protocol (Thermo Fischer Scientific, Waltham, MA, USA). 
Viral load was quantified from nasopharyngeal swabs at 
IrsiCaixa laboratory (Badalona, Spain) by PCR amplifi-
cation, on the basis of the 2019 novel coronavirus real-
time RT-PCR diagnostic panel guidelines and protocol 
developed by the US Centers for Disease Control and 
Prevention.23 For absolute quantification, a standard curve 
was built using 1/5 serial dilutions of a SARS-CoV-2 
plasmid (2019-nCoV_N_Positive Control, 2 × 10⁵ copies 
Value
Cluster size 2 (1–3)
Index cases (n=282)




Log viral load 8 (6–9)
Contacts (n=753)





Baseline positive PCR of contact case 93 (12%)
Form of contact
Health-care worker 254 (34%)
Household 382 (51%)
Nursing home 21 (3%)
Unknown 96 (13%)
Data are n (%), mean (SD), or median (IQR).
Table 1: Baseline characteristics of linked transmission clusters
See Online for appendix 2
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per μL, Integrated DNA Technologies, Coralville, IA, 
USA) and run in parallel to all PCR determinations.
Outcomes and definitions
Transmission was characterised by examining the 
number of individuals infected and uninfected among 
close contacts of an index case. We defined transmission 
events as PCR positivity at any timepoint (ie, days 1, 14, or 
at any other unscheduled PCR testing when participants 
referred symptoms) of a contact in the same household 
or workplace within 14 days after enrolment. We defined 
secondary attack rate of viral transmission as the ratio of 
individuals with a positive PCR test among close contacts, 
according to WHO guidelines.
Development to symptomatic disease was defined as 
presence of at least one of the following symptoms: 
fever, cough, difficulty breathing, myalgia, headache, sore 
throat, new olfactory and taste disorder, or diarrhoea) 
and a positive SARS-CoV-2 RT-PCR test. The incubation 
period was defined as time from first exposure to symptom 
onset, with later confirmation of infection by PCR.24 The 
earliest possible exposure with the symptomatic index case 
was determined for each contact individually.
Statistical analysis
We used log-transformed viral loads that were approxi-
mately normally distributed and that also aligned with 
common reporting norms. The relationship between 
characteristics of cases and viral load was assessed by use 
of linear regression considering age (in years), sex, 
number of days from reported symptom onset, and 
presence or absence of five key clinical features: fever, 
cough, dyspnoea, rhinitis, and anosmia. To identify risk 
factors for transmission, we used logistic regression 
modelling for the risk of transmission using a random-
effect model to allow for within-cluster variation in the 
risk of transmission. Factors with potential influence on 
the risk of transmission included characteristics of the 
potential transmitter (ie, age, sex, viral load, and the 
presence or absence of respiratory symptoms) and 
contacts (ie, age, sex, and the type of contact they had with 
the index case). Finally, the risk of developing symptomatic 
COVID-19 was assessed by fitting a Cox-regression model 
considering the age (in years) and sex of the individual, 
the presence or absence of cardiovascular disease and 
chronic respiratory disease, and the initial viral load 
relative to the time to development of symptomatic 
disease. Data at 14 days after the first study visit were 
censored, in line with the follow-up done in the original 
trial. All analyses were done in R, version 4.0.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between March 17 and April 28, 2020, we identified 
314 patients with COVID-19 in whom the viral load was 
tested. Of these, 220 (70%) were women, 94 (30%) were 
men, and the median age was 41 years (IQR 31–52). Of 
the 314 patients, 282 (90%) had at least one close contact, 
resulting in 282 corresponding clusters with a total of 
753 contacts. Clusters had a median of two contacts 
(IQR 1–3) and a maximum of 19 contacts. Most index 
cases of the clusters were women (202 [72%]), with an 
average age of 42 years (SD 13; table 1).
The first study visit was done a median of 4 days 
(IQR 3–5) after symptom onset. At the first study visit, 
the median viral load among patients with COVID-19 
was 1 × 110⁸ copies per mL (IQR 1 × 110⁶ to 1 × 10⁹). In 
multivariable linear regression, the viral load among 
cases was positively associated with the presence of fever 
and negatively associated with the presence of anosmia 
(table 2), but no association was observed with age or sex 
of the COVID-19 case nor with the presence of reported 
dyspnoea or cough. As anticipated, viral load was 
negatively associated with the number of days from 
symptom onset.
For our risk factor analysis on SARS-CoV-2 trans-
mission, we used linked case and contact data of 
282 clusters with 753 contacts. At the cluster level, 
Log10 viral load 
per mL
Unadjusted 
β coefficient (95% CI)
p value Adjusted 
β coefficient (95% CI)
p value
Case age NA 0·00 (–0·02 to 0·02) 0·78 0·01 (–0·01 to 0·02) 0·38
Case sex
Men 8·15 (7·54 to 8·77) Reference ·· Reference ··
Women 8·04 (7·47 to 8·60) –0·24 (–0·72 to 2·40) 0·33 –0·22 (–0·61 to 0·34) 0·59
Days from 
symptom onset
NA –0·17 (–0·26 to 0·08) 0·0002 –0·16 (–0·24 to 0·07) 0·0004
Symptoms
Cough
Absent 7·82 (7·24 to 8·41) Reference ·· Reference ··
Present 8·37 (7·78 to 8·95) 0·66 (0·22 to 1·10) 0·0032 0·41 (–0·02 to 0·84) 0·055
Dyspnoea
Absent 7·97 (7·50 to 8·43) Reference ·· Reference ··
Present 8·22 (7·45 to 8·99) 0·27 (–0·40 to 0·94) 0·42 0·28 (–0·35 to 0·92) 0·38
Fever
Absent 7·77 (7·16 to 8·38) Reference ·· Reference ··
Present 8·42 (7·86 to 8·98) 0·80 (0·36 to 1·24) 0·0004 0·43 (0·00 to 0·87) 0·054
Anosmia
Absent 8·32 (7·76 to 8·88) Reference ·· Reference ··
Present 7·87 (7·25 to 8·49) –0·57 (–1·00 to –0·09) 0·019 –0·54 (–1·00 to 0·09) 0·019
Rhinitis
Absent 7·60 (7·23 to 7·98) Reference ·· Reference ··
Present 8·59 (7·65 to 9·52) 0·88 (–0·05 to 1·82) 0·064 0·77 (–0·11 to 1·66) 0·087
NA=not applicable.
Table 2: Univariable and multivariable linear regression of association between index case variables and 
log10 viral load
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90 (32%) of 282 clusters had at least one transmission 
event, with a highly skewed distribution of the number of 
transmission events per cluster (figure 1A). The first visit 
for contacts took place a median of 5 days (IQR 4–7) after 
their first possible exposure to the index case. 125 (17%) of 
753 contacts had a PCR positive result over the study 
period. The proportion of contacts who tested positive for 
SARS-CoV-2 within a cluster (secondary attack rate) 
progressively increased with the viral load of the index 
case: from 12% when the index case had a viral load lower 
than 1 × 10⁶ copies per mL to 24% when the index case had 
a viral load of 1 × 10¹⁰ copies per mL or higher (figure 1B). 
According to the multivariate analysis, the viral load of 
the index case was strongly associated with the risk of 
onward transmission (adjusted odds ratio per log10 
increase in viral load 1·3, 95% CI 1·1–1·5; table 3). 
114 (90%) of 125 transmission events occurred in clusters 
where the index case had a viral load of 5·1 log10 copies 
per mL or higher, and 61 (50%) occurred in clusters where 
the index case had a viral load of 8·8 log10 copies per mL or 
higher. Other factors associated with an increased risk of 
transmission were household contact (adjusted OR 3·0, 
95% CI 1·59–5·65) and age of the contact (1·02, 1·01–1·04). 
We observed no association of risk of transmission with 
reported mask usage by contacts, with the age or sex of 
the index case, or with the presence of respiratory 
symptoms in the index case at the initial study visit 
(table 3).
We did not find any evidence of an association 
between the viral load of the index cases and the 
first viral load of incident positive results among 
contacts (p=0·10, appendix 2 p 2), and this remained 
true when adjusting for both the day of illness on which 
the baseline viral load of the index case was measured 
and the number of days until the contact was enrolled 
(p=0·18). Additionally, after excluding contacts who 
were PCR positive at the first study visit, we found no 
association between the viral load of the index case and 
Figure 1: Transmission in a cluster
(A) Number of secondary cases per cluster. (B) Relationship between viral load 
of the index case and the proportion of contacts developing COVID-19: 36 of 
284 contacts in group <1 × 110⁷ copies per mL, 72 of 398 in group 1 × 110⁷ to 
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Unadjusted odds ratio 
(95% CI)




Age, per year 1·02 (0·99–1·05) 0·069 1·01 (0·99–1·03) 0·46
Sex
Men 1 (ref) NA 1 (ref) NA
Women 0·74 (0·40–1·36) 0·33 0·71 (0·37–1·39) 0·32
Viral load, per log10 change 1·27 (1·09–1·48) 0·0020 1·29 (1·10–1·50) 0·0012
Cough 1·00 (0·55–1·82) 0·99 1·13 (0·64–2·00) 0·66
Dyspnoea 0·80 (0·31–2·07) 0·64 0·75 (0·30–1·89) 0·55
Rhinitis 1·46 (0·46–4·63) 0·52 1·31 (0·42–4·11) 0·64
Contact
Age, per year 1·03 (1·01–1·05) 0·0085 1·02 (1·01–1·04) 0·0008
Sex
Men 1 (ref) NA 1 (ref) NA
Women 0·93 (0·58–1·49) 0·77 1·33 (0·79–2·23) 0·28
Mask use by the contact
Never 1 (ref) NA 1 (ref) NA
Always 0·93 (0·47–1·83) 0·84 1·55 (0·76–3·16) 0·23
Unknown 1·18 (0·59–2·36) 0·47 1·49 (0·74–3·01) 0·26
Contact type
Health-care work 1 (ref) NA 1 (ref) NA
Household 3·07 (1·68–5·62) 0·0003 3·00 (1·59–5·65) 0·0006
Nursing home 1·75 (0·19–16·01) 0·62 1·90 (0·30–1·91) 0·49
Other 0·32 (0·03–3·05) 0·32 1·19 (0·10–4·31) 0·89
NA=not applicable. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
Table 3: Risk factors for transmission of SARS-CoV-2
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the time to onset of incident SARS-CoV-2 infection 
(hazard ratio [HR] 1·01, 95% CI 0·83–1·23).
Overall, 449 contacts had a positive PCR result at first 
visit, whether viral load data of their index case was 
available (n=125) or not (n=324). 28 (6%) of 449 contacts 
had symptoms at the first visit. Of 421 contacts who were 
asymptomatic at the first visit, 181 (43%) developed 
symptomatic COVID-19 within the follow-up period. The 
multivariable cox-regression analysis, after adjusting for 
age and sex, showed that increasing viral load levels of the 
contact at day 1 were associated with an increased risk of 
developing symptomatic disease. Among contacts not 
already symptomatic at baseline, the risk of symptomatic 
disease was approximately 38% among individuals with 
an initial viral load lower than 1 × 10⁷ copies per mL 
compared with a risk greater than 66% among those with 
an initial viral load of 1 × 110¹⁰ copies per mL or higher 
(HR per log10 increase in viral load 1·12, 95% CI 1·05–1·20; 
p=0·0006; figure 2A). In the multi variable analysis, no 
association was found between sex or age of individuals, 
the presence of diabetes, or presence of cardiovascular or 
respiratory disease and the risk of or time to developing 
symptomatic COVID-19.
The median time from exposure to symptom onset was 
7 days (IQR 5–9). The time to onset of symptomatic 
disease decreased from a median of 7 days (5–10) 
for individuals with an initial viral load lower than 
1 × 10⁷ copies per mL to 6 days (4–8) for those with an 
initial viral load between 1 × 10⁷ and 1 × 10⁹ copies per mL, 
and 5 days (3–8) for those with an initial viral load of 
1 × 10¹⁰ copies per mL or higher (figure 2B). Overall, 
110 (61%) of 181 participants who developed symptoms 
did so before day 8, 45 (25%) between days 8–10, and 
22 (12%) between days 11–14.
Discussion
In our study, we found that increasing viral load values 
in nasopharyngeal swabs of patients with COVID-19 
were associated with the greater risk of transmission, 
measured by SARS-CoV-2 PCR positivity among contacts, 
and with a higher risk of transmission in a household 
environment compared with that in other indoor 
situations. Additionally, we found that higher viral loads 
in swabs of asymptomatic contacts were associated with 
higher risk of developing symptomatic COVID-19, and 
that these contacts had shorter incubation periods than 
those with a lower viral load. Relationships between 
viral load and infectivity have been described for other 
respiratory viruses, and our study shows that the same is 
true for SARS-CoV-2.
To our knowledge, this is the largest study that 
evaluated the relationship of viral load in patients with 
COVID-19 and risk of transmission. In our cohort, a 
high proportion (192 [68%] of 282) of index cases did not 
cause secondary infections. However, we identified 
90 (32%) clusters with transmission events, and the 
multivariate analysis revealed that clusters centred on 
index cases with high viral load were significantly more 
likely to result in transmission. In line with previous 
analyses of case-contact clusters,9,12,14 we also found that 
household exposure to an index case was associated 
with a higher risk of transmission than other types of 
contact, presumably reflecting duration and proximity of 
exposure. Increasing age of the contact was also identi-
fied in our multivariate analysis as a significant–albeit 
modest–determinant of transmission risk. This factor 
has shown uneven influence across results reported 
elsewhere but seems to play a secondary role among 
adults.13,14 Finally, unlike previous analyses that reported 
a relationship between coughing and transmission,13 we 
did not find any association. This finding suggests that 
Figure 2: Risk of developing symptomatic COVID-19 according to 
characteristics of the contact at enrolment
(A) Probability of symptomatic disease by viral load. (B) Time to symptomatic 
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the absence of cough does not preclude significant 
onward transmission, particularly if the viral load is 
high. Taken together, our results indicate that the viral 
load, rather than symptoms, might be the predominant 
driver of transmission.
Importantly, we report that high viral load shortly 
after exposure in asymptomatic contacts was strongly 
associated with the risk of developing symptomatic 
COVID-19 disease. We found an approximately 40% risk 
of developing symptomatic disease among individuals 
with an initial viral load lower than 1 × 10⁷ copies per mL 
compared with a risk higher than 66% among individuals 
with a viral load of 1 × 110¹⁰ copies per mL or higher. 
These data might provide rationale for risk stratification 
for developing illness. Moreover, the initial viral load 
significantly shifted the incubation time, which ranged 
from 5 days in participants with a high viral load to 7 days 
in participants with a low viral load. To our knowledge, 
our study was the first analysis of prospective data that 
investigated the association between initial viral load and 
incubation time.
The study has several limitations. First, asymptomatic 
people were not enrolled as index cases, affecting our ability 
to fully characterise all types of transmission chain. Second, 
we did not find any evidence of decreased risk of 
transmission in individuals who reported mask use. 
Although this finding collides with the evidence reported 
elsewhere,8 we did not have fine-grained data on type of 
mask (surgical vs FFP2) or use of other measures of 
personal protective equipment (PPE) or other infection 
control practices, thus limiting our ability to make clear 
inferences about the effect of PPE on transmission risk. 
Mask use is probably correlated with type of exposure, 
which might further confound associations, but we did not 
note any association between mask use and risk either in 
our unadjusted analysis (table 3) or in a multivariable 
model excluding type of exposure (data not shown). Third, 
we used time to symptom onset (with later confirmation of 
infection) rather than time to positive PCR test based on 
serial testing. Nonetheless, accurate calculation of the 
incubation period was feasible because of the prospective 
nature of the study, accurate identification of exposure by 
face-to-face interview, and intensive active and passive 
monitoring of exposed contacts. We followed up 
participants over 14-day periods, thus incubation periods 
longer than 14 days might not have been detected. Within 
each cluster, we cannot be completely certain about the 
directionality of trans mission, but our inclusion criteria 
including the absence of COVID-19-like symptoms in 
the 2 weeks preceding enrolment is consistent with 
transmission from a case to a contact. We also cannot 
exclude that some individuals might have been infected by 
individuals outside of study clusters but, as per national 
guidelines, all contacts were quarantined after exposure to 
index cases, reducing the chance of transmission from 
elsewhere. Samples were available from index cases a 
median of 4 days after symptom onset, and the initial 
sample in contacts was taken on average 5 days after 
exposure, which might limit our ability to detect 
associations with peak viral load. Despite this, we still 
showed clear dose effects in relation to both risk of 
transmission and time to symptom onset. Finally, our 
study population is reflective of the trial from which the 
study sample was drawn and is, therefore, biased towards 
female participants and participants with few comorbidities 
and predominantly mild to moderate infection; additional 
data are needed on the risk of transmission in other 
populations.
In summary, our results provide evidence regarding the 
determinants of SARS-CoV-2 transmission, par ticularly on 
the role of the viral load. The higher risk of transmission 
among individuals with higher viral loads adds to existing 
evidence and encourages the assessment of the viral load 
in patients with a large number of close contacts. When a 
patient with high viral load is identified, the implementation 
of reinforced contact tracing measures and quarantines 
might be crucial to reduce onward transmission. 
Similarly, our results regarding the risk and expected time 
to developing symptomatic COVID-19 encourage risk 
stratification of newly diagnosed SARS-CoV-2 infections 
on the basis of initial viral load.
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